AstraZeneca (AZN) Report Interpretation

Overview

Goldman Sachs reviews AstraZeneca's commercial opportunity for the Claudin 18.2-targeting antibody-drug conjugate sonesitatug vedotin (sone-ve) after positive CLARITY-Gastric01 topline data. The report concludes that management's $3-5bn peak-sales guidance is achievable, but that the larger first-line opportunity depends on the ongoing CLARITY-Gastric02 study.

Core views

Goldman Sachs estimates that sone-ve can generate $3.7bn of unrisked peak sales across gastric-cancer treatment lines, broadly supporting AstraZeneca management's $3-5bn guidance. Its risk-adjusted peak-sales estimate is $2.4bn, with the analysis separating 3L+ ($414mn unrisked), 2L ($1.264bn), and 1L ($2.9bn) opportunities and adjusting for cannibalization between earlier and later treatment lines. The resulting estimate is 85% above VA consensus peak-sales forecasts; Goldman Sachs believes consensus forecasts are largely achievable from the 2L+ opportunity alone and sees scope for mid- to long-term upward revisions. The clinical evidence produces a differentiated regulatory outlook by treatment line. CLARITY-Gastric01 met the overall-survival endpoint in 3L+ patients and showed statistically significant overall-survival benefit in 2L+ patients as a secondary endpoint, but missed the co-primary progression-free-survival endpoint in 2L+. Goldman Sachs is therefore positive on approval in 3L+ but comparatively cautious on 2L approval. At the detailed data release, it will focus on 2L overall-survival and progression-free-survival outcomes, whether their relationship is internally consistent, and regional consistency, particularly because AstraZeneca epidemiology data indicate substantially more patients in China and Japan than in the US and EU. The report benchmarks the expected later-line data against established studies. For 2L treatment, it uses RAINBOW data for Cyramza plus paclitaxel as the relevant bar: progression-free survival of 4.4 months, overall survival of 9.6 months, and an objective response rate of 28%. For 3L+, it uses TAGS data for Lonsurf: progression-free survival of 2 months, overall survival of 5.7 months, and an objective response rate of 4.5%. Goldman Sachs says AstraZeneca's description of the topline data as highly clinically meaningful supports confidence in the efficacy signal, while detailed data will determine how robust that signal is versus these benchmarks. For its US commercial model, Goldman Sachs estimates about 18,000 newly diagnosed, drug-eligible locally advanced or metastatic gastric-cancer patients in 2027. It assumes 63% have CLDN18.2 expression above 25%, yielding about 11,000 first-line patients eligible for sone-ve; 70% of these patients progress to eligibility for 2L therapy, or about 7,800 people, and 70% of 2L patients are eligible for 3L therapy, or about 5,500 people. The model assumes a US list price of about $200,000 per year, broadly in line with Enhertu. It assigns probabilities of success of 90% for 3L+, 70% for 2L, and 60% for 1L. The first-line trial, CLARITY-Gastric02, is ongoing with primary completion/readout expected in August 2029, making it central to realization of the full opportunity. Goldman Sachs finds additional support for the first-line forecast in Vyloy, another CLDN18.2-targeting treatment. Vyloy was approved in October 2024 for first-line gastric or gastroesophageal-junction adenocarcinoma in patients with expression above 75%; in SPOTLIGHT, Vyloy plus chemotherapy produced progression-free survival of 10.6 versus 8.7 months and overall survival of 18.2 versus 15.5 months, both with a hazard ratio of 0.75. The report notes Vyloy's $396mn sales in 2025 and consensus peak-sales forecast of $1bn as supportive context. It also expects investors to scrutinize sone-ve efficacy in patients previously treated with Vyloy, although it does not exclude that population from its model. The report materially raises sone-ve expectations: risk-adjusted peak sales increase fourfold to $2.4bn from $478mn. It also lowers volrustomig's unrisked peak-sales estimate to about $2.5bn from $4.5bn after the failed eVOLVE-Lung02 trial, raises the probability of success for Enhertu's DESTINY-Lung04 trial in first-line HER2-positive lung cancer to 90% from 75% following positive topline data, and updates early-stage assets after AstraZeneca's 2Q26 release. Net of these changes, total-revenue forecasts are broadly unchanged through FY26-34 and 3% higher in FY35-36, as higher sone-ve and Enhertu assumptions offset lower volrustomig estimates. Goldman Sachs maintains a Buy rating. Its 12-month target price is raised to 16,300p/$216 from 16,070p/$213, based on an equal weighting of a bottom-up DCF valuation of 16,094p per share and a 2027E P/E valuation of 16,479p per share. The DCF uses an unchanged 8.0% WACC and 2.5% terminal growth rate, while the multiples valuation applies 20x 2027E EPS. The report also argues that the positive sone-ve data provide an incremental proof point for AstraZeneca's R&D capability after investor caution related to the CARDIO-TTRansform miss and merger speculation.

Analysis framework

Goldman Sachs combines clinical-trial assessment with a bottom-up commercial model. It benchmarks efficacy against later-line standards of care, estimates eligible patient pools and treatment-line progression, applies price and probability-of-success assumptions, then incorporates updated pipeline forecasts into revenue estimates and values AstraZeneca using an equal blend of DCF and 2027E P/E.

Methodology notes

• Industry AnalysisSupply-demand framework

  Bottom-up patient-based commercial opportunity model

  The report estimates eligible gastric-cancer patients, biomarker prevalence, movement through treatment lines, assumed price, and expected uptake to derive peak sales for sone-ve.

• Valuation methodsDCF (Discounted Cash Flow)

  Bottom-up DCF valuation

  Goldman Sachs discounts forecast cash flows using an 8.0% WACC and 2.5% terminal growth rate to derive a 16,094p per-share valuation.

• Valuation methodsP/E and PEG Valuation

  Forward P/E valuation

  The report applies a 20x multiple to 2027E EPS, producing a 16,479p per-share valuation that is blended equally with the DCF result.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• AstraZeneca (AZN.L)

  Primary covered company; sone-ve's gastric-cancer opportunity is presented as a potential driver of mid- to long-term estimate revisions.

  Strengths

  Positive sone-ve topline data, a modeled $3.7bn unrisked peak-sales opportunity, and additional support for AstraZeneca's R&D reputation.

  Weaknesses

  The 2L+ CLARITY-Gastric01 trial missed its progression-free-survival co-primary endpoint.

  Comparison

  The report benchmarks 2L efficacy against Cyramza plus paclitaxel in RAINBOW and 3L+ efficacy against Lonsurf in TAGS.

  Risks

  Clinical-trial failure, commercial execution, pricing, competitive developments, and patent exposure.

Key data

• Sone-ve unrisked peak sales$3.7bnCombined gastric-cancer opportunity across 1L, 2L and 3L+, adjusted for cannibalization.
• Sone-ve risk-adjusted peak sales$2.4bnUp fourfold from Goldman Sachs' prior $478mn estimate.
• First-line sone-ve peak sales$2.9bn unrisked / $1.7bn risk-adjustedBased on a 60% probability of success; CLARITY-Gastric02 readout is expected in August 2029.
• Second-line sone-ve peak sales$1.264bn unrisked / $0.9bn risk-adjustedBased on a 70% probability of success after the PFS miss but OS benefit in CLARITY-Gastric01.
• Third-line-plus sone-ve peak sales$414mn unrisked / $0.4bn risk-adjustedBased on a 90% probability of success and positive 3L+ overall-survival data.
• US addressable patient basec. 18K patients in 2027Newly diagnosed, drug-eligible locally advanced and metastatic gastric-cancer patients; 63% are assumed CLDN18.2-positive above 25%.
• Price target16,300p/$216Raised from 16,070p/$213; derived from a 50:50 DCF and P/E blend.
• FY35-36 total revenue forecast change+3%Higher sone-ve and Enhertu assumptions more than offset lower volrustomig assumptions.

Impact & implications

The report views sone-ve as a meaningful potential contributor to AstraZeneca's longer-term growth and as a source of upward estimate revisions if its clinical and regulatory profile develops as modeled. Nearer-term confidence rests on detailed CLARITY-Gastric01 data and on how the asset compares with existing later-line standards, while the full commercial case depends on first-line success in 2029.

Risks

• Clinical-trial failure could reduce the value assigned to sone-ve and other pipeline assets.
• Commercial execution may prevent modeled sales from being achieved.
• Pricing pressure, competitive developments, and patent exposure are key risks to Goldman Sachs' view and price target.
• A 2L regulatory outcome is less certain because CLARITY-Gastric01 missed the 2L+ progression-free-survival co-primary endpoint.

What to watch

• Detailed CLARITY-Gastric01 data, especially 2L progression-free and overall-survival results and their consistency across regions.
• Sone-ve efficacy in patients previously treated with Vyloy.
• CLARITY-Gastric02 first-line data, with readout expected in August 2029.
• Tozorakimab Phase 3 COPD presentations at ERS on 5-9 September.
• SERENA-4 topline data, the FDA decision for camizestrant in the SERENA-6 switch setting, and AVANZAR data for Datroway plus Imfinzi in first-line NSCLC.